Towards defining the Immunogenicity of HLA Epitopes: Impact of HLA Class I Eplets on Antibody Formation during Pregnancy

Eplets are functional units of structural epitopes on donor Human Leukocyte Antigens (HLA), potentially recognized by complementarity-determining regions of the paratope of the recipients' B cell receptors or antibodies (Ab). Their individual immunogenicity is poorly described, yet this feature would be of clinical importance for pre-transplant risk assessment. The aim of this study was to determine the relative immunogenicity of HLA class I eplets in the pregnancy setting, where mismatched eplets are present on paternal HLA antigens of the unborn child. One hundred fifty-nine predominantly Caucasian mothers giving birth at the University Hospital Basel and their first newborns were HLA-typed at high resolution by Next Generation Sequencing (NGS) (NGSgo® Workflow and NGSengine® from GenDx; sequencing with a Miseq™ from Illumina® ) and eplets were determined using HLAMatchmaker. HLA class I specific IgG Ab were assessed in maternal sera drawn immediately after full term delivery, by OneLambda LABScreen™ single antigen ibeads. The Ab profile was subsequently evaluated for eplet-associated patterns. All 72 currently Ab-verified HLA class I eplets were examined for their immunogenicity according to the frequency of child-specific HLA Ab (CSA) directed against their structures. Four hundred twelve of 477 (86.4%) paternal HLA-A, -B or -C alleles were mismatched. CSA were present in 46 mothers (28.9%), directed against 80 (19.4%) of these mismatches. The ten most immunogenic eplets were 62GK, 145KHA, 144TKH, 107W, 62GE, 80I, 82LR, 41T, 127K, 45KE with immunogenicity rates between 45.8%-27.3%. This pregnancy study also identified five non-reactive eplets: 62RR,76ESN, 80TLR,156DA,163RW. Based on our results, immunogenic hot and cold spots on the surface of HLA class I molecules were localized and visualized on 3D models. This study strengthens the presumption that different eplets represent different immunogenic potentials. Validation of these results in the clinical transplant setting is an essential next step in identifying those eplets representing a particularly high-risk potential. This article is protected by copyright. All rights reserved.